MedPath

AMERICAN REGENT, INC.

AMERICAN REGENT, INC. logo
🇺🇸United States
Ownership
Subsidiary
Established
1967-01-01
Employees
501
Market Cap
-
Website
http://www.americanregent.com

Clinical Trials

64

Active:6
Completed:46

Trial Phases

5 Phases

Phase 1:8
Phase 2:15
Phase 3:25
+2 more phases

Drug Approvals

44

FDA:44

Drug Approvals

Calcium Chloride

Approval Date
Mar 26, 2024
FDA

PROVAYBLUE

Approval Date
Feb 12, 2024
FDA

Glycopyrrolate

Approval Date
Feb 7, 2024
FDA

Papaverine Hydrochloride

Approval Date
Nov 17, 2023
FDA

Cyanocobalamin

Approval Date
Oct 31, 2023
FDA

Levocarnitine

Approval Date
Jun 23, 2023
FDA

Injectafer

Approval Date
May 1, 2023
FDA

Droperidol

Approval Date
Mar 20, 2023
FDA

Vasopressin

Approval Date
Jan 1, 2023
FDA

Olanzapine

Approval Date
Nov 22, 2022
FDA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next

Clinical Trials

Distribution across different clinical trial phases (59 trials with phase data)• Click on a phase to view related trials

Phase 3
25 (42.4%)
Phase 2
15 (25.4%)
Phase 1
8 (13.6%)
Phase 4
7 (11.9%)
Not Applicable
4 (6.8%)

Safety and Tolerability of 200mg and 100mg of Venofer Administered to Hemodialysis(HD) Patients

Phase 4
Completed
Conditions
Hemodialysis
Interventions
First Posted Date
2024-11-15
Last Posted Date
2024-11-15
Lead Sponsor
American Regent, Inc.
Target Recruit Count
400
Registration Number
NCT06690450

Tralement vs. Fixed-dose Trace Element Combination Product in Patients >3 to 17 Years of Age Requiring Long-term PN

Phase 4
Withdrawn
Conditions
Manganese Safety in Pediatric Patients
Interventions
Drug: Fixed-dose trace element combination product of zinc, copper, and selenious acid
First Posted Date
2023-01-10
Last Posted Date
2024-11-15
Lead Sponsor
American Regent, Inc.
Target Recruit Count
80
Registration Number
NCT05677126

Tralement Versus a Fixed-dose Trace Element Combination Product to Evaluate Manganese Safety

Phase 4
Withdrawn
Conditions
Manganese Safety in Adults
Interventions
Drug: Fixed-dose trace element combination product of zinc, copper, and selenious acid
First Posted Date
2022-12-22
Last Posted Date
2025-02-12
Lead Sponsor
American Regent, Inc.
Target Recruit Count
108
Registration Number
NCT05661682

Safety, Tolerability, PK and PD of Intravenous Ferric Carboxymaltose in Infants With Iron Deficiency Anemia

Phase 2
Withdrawn
Conditions
Iron Deficiency, Anaemia
Interventions
First Posted Date
2021-07-20
Last Posted Date
2023-01-06
Lead Sponsor
American Regent, Inc.
Registration Number
NCT04968379
Locations
🇺🇸

University of Iowa, Iowa City, Iowa, United States

🇺🇸

Cohen Children's Medical Center, New Hyde Park, New York, United States

🇺🇸

Nationwide Children's Hospital, Columbus, Ohio, United States

and more 1 locations

Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia and Unsatisfactory Response Oral Iron Under Study Protocol 1VIT17044

Phase 3
Completed
Conditions
Iron Deficiency Anemia
Interventions
First Posted Date
2020-02-17
Last Posted Date
2022-03-21
Lead Sponsor
American Regent, Inc.
Target Recruit Count
7
Registration Number
NCT04269707
Locations
🇺🇸

South Florida Research Phase I-IV, Miami Springs, Florida, United States

🇺🇸

Miami Clinical Research, Miami, Florida, United States

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 11
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.